Skip to content

PetLife Pharmaceuticals, Inc.: 10-Q filed 2018-07-17

What PetLife Pharmaceuticals, Inc. reported in its quarterly report filed 2018-07-17 (fiscal Q2 2018): 17 published measures, 44 facts as tagged in accession 0001493152-18-010103.

This filing

Form
10-Q (quarterly report)
Filed
2018-07-17
Fiscal period
fiscal Q2 2018
Accession
0001493152-18-010103 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All PetLife Pharmaceuticals, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2018-02-287,856USD
At 2017-08-3155,004USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2018-02-281,980,970USD
At 2017-08-311,436,454USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2018-02-28-1,973,114USD
At 2017-08-31-1,381,450USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2018-02-287,856USD
At 2017-08-3154,254USD
At 2017-02-28445USD
At 2016-08-311,172USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2017-12-01 to 2018-02-28-427,064USD90
2017-09-01 to 2018-02-28-893,724USD181
2016-12-01 to 2017-02-28-1,316,781USD90
2016-09-01 to 2017-02-28-20,442,415USD181

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2017-09-01 to 2018-02-28-282,396USD181
2016-09-01 to 2017-02-28-339,409USD181

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2017-09-01 to 2018-02-28236,000USD181
2016-09-01 to 2017-02-28338,682USD181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2018-02-28-31,281,904USD
At 2017-08-31-30,388,180USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2017-12-01 to 2018-02-2840,110USD90
2017-09-01 to 2018-02-28115,859USD181
2016-12-01 to 2017-02-281,212,735USD90
2016-09-01 to 2017-02-2820,006,174USD181

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2017-12-01 to 2018-02-28-182,670USD90
2017-09-01 to 2018-02-28-375,980USD181
2016-12-01 to 2017-02-28-1,254,937USD90
2016-09-01 to 2017-02-28-20,368,405USD181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2018-02-287,856USD
At 2017-08-3155,004USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2018-02-281,980,970USD
At 2017-08-311,436,454USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2018-02-28295,061USD
At 2017-08-31307,478USD

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2018-02-2880,256,702shares
At 2017-08-3173,842,320shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2018-02-2829,225,283USD
At 2017-08-3128,929,638USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2018-02-28233,897USD
At 2017-08-31223,897USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2017-12-01 to 2018-02-28142,560USD90
2017-09-01 to 2018-02-28260,121USD181
2016-12-01 to 2017-02-2842,202USD90
2016-09-01 to 2017-02-28362,231USD181

Inspect the source

Entity
PetLife Pharmaceuticals, Inc. / CIK 0001354591
Captured
SEC response SHA-256
41a0ceb8f85d25ccf92688c1e58fdda5b8df53bc4f4e1ac81b38afabe0cc1efa

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001354591.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))